Shares of Novo Nordisk (NYSE: NVO) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Novo Nordisk (NVO) stock shed over 21% on Tuesday after the Danish pharmaceutical giant slashed its guidance for the second time this year, leaving investors questioning whether the obesity drug ...

(Reuters) -Shares in Wegovy maker Novo Nordisk fell around 4% on Friday to their lowest since August 2021, after U.S.

Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...

Novo Nordisk (NVO) downgraded to Hold by HSBC amid growth concerns, GLP-1 market challenges, and revised 2025-2026 earnings ...

Kumar now believes the stock is only worthy of a hold recommendation, down from his previous assessment of buy. He also significantly lowered his price target, chopping it to 360 Danish krone ($55.49) ...

Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs.

Novo moves past GLP-1 spat with Hims & Hers, tapping telehealth company to offer discounted Wegovy By Andrea Park Apr 29, 2025 11:05am Novo Nordisk Wegovy semaglutide Hims & Hers ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

Danish leader will face a challenging landscape among competitors ...